ABL Bio Inc (298380) - Total Assets
Based on the latest financial reports, ABL Bio Inc (298380) holds total assets worth ₩298.13 Billion KRW (≈ $202.04 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 298380 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
ABL Bio Inc - Total Assets Trend (2016–2025)
This chart illustrates how ABL Bio Inc's total assets have evolved over time, based on quarterly financial data. Explore 298380 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
ABL Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ABL Bio Inc's total assets of ₩298.13 Billion consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 39.9% |
| Accounts Receivable | ₩59.11 Billion | 21.0% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.87 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how ABL Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ABL Bio Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABL Bio Inc's current assets represent 62.7% of total assets in 2025, a decrease from 75.6% in 2016.
- Cash Position: Cash and equivalents constituted 39.9% of total assets in 2025, down from 70.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 21.0% of total assets.
ABL Bio Inc Competitors by Total Assets
Key competitors of ABL Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
ABL Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 1.70 | 12.87 |
| Quick Ratio | 1.70 | 1.70 | 12.87 |
| Cash Ratio | 0.00 | 0.35 | 4.90 |
| Working Capital | ₩79.54 Billion | ₩46.51 Billion | ₩58.17 Billion |
ABL Bio Inc - Advanced Valuation Insights
This section examines the relationship between ABL Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.20 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | ₩280.93 Billion |
| Market Capitalization | $3.70 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ABL Bio Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ABL Bio Inc's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABL Bio Inc (2016–2025)
The table below shows the annual total assets of ABL Bio Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩280.93 Billion ≈ $190.39 Million |
+21.11% |
| 2024-12-31 | ₩231.98 Billion ≈ $157.21 Million |
+44.85% |
| 2023-12-31 | ₩160.14 Billion ≈ $108.53 Million |
-13.52% |
| 2022-12-31 | ₩185.18 Billion ≈ $125.49 Million |
+182.92% |
| 2021-12-31 | ₩65.45 Billion ≈ $44.36 Million |
-34.48% |
| 2020-12-31 | ₩99.89 Billion ≈ $67.70 Million |
-30.10% |
| 2019-12-31 | ₩142.90 Billion ≈ $96.84 Million |
-15.38% |
| 2018-12-31 | ₩168.87 Billion ≈ $114.44 Million |
+729.02% |
| 2017-12-31 | ₩20.37 Billion ≈ $13.80 Million |
+170.50% |
| 2016-12-31 | ₩7.53 Billion ≈ $5.10 Million |
-- |
About ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more